We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Derivation of New Human Embryonic Stem Cell Lines Lines for Clinical Use

This study is currently recruiting participants.
Verified February 2017 by Hadassah Medical Organization
Sponsor:
ClinicalTrials.gov Identifier:
NCT00353197
First Posted: July 18, 2006
Last Update Posted: March 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Hadassah Medical Organization
  Purpose

Human embryonic stem cells (hESCs) are isolated from the early human embryo and have the capability to proliferate indefinitely in culture and to develop into nearly every cell of the human body. Therefore, hESCs may serve as a renewable unlimited source of cells for transplantation therapy. Because of the use of animal products in their derivation, and due to the lack of appropriate quality and process controls in the manufacturing of existing cell lines worldwide, existing hESC lines are not suitable for utilization in transplantation therapy.

Our objective is to derive several new hESC lines that will be suitable for clinical trials. The investigators plan on deriving the new hESC lines utilizing only FDA-approved raw materials in a non-animal culture system. They will be produced entirely under GMP conditions, using appropriately documented procedures and analytical methods, completely safety tested, and screened for infectious and adventitious agents.


Condition
Infertility

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Other
Official Title: The Derivation of New Human Embryonic Stem Cell Lines for Clinical Use

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention:   Samples With DNA
Blood serum samples of donor couple.

Estimated Enrollment: 40
Actual Study Start Date: July 2002
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Embryo donors who have derived embryos via IVF and have surplus embryos that they will not use for family-building.
Criteria

Inclusion Criteria:

  • Couple has embryos derived through IVF that they wish to donate to research.
  • Couple has finished building their family.
  • Couple has them stored in liquid nitrogen for > or = to 5 years.
  • Couple will submit to an interview, blood tests, and physical exam by a physician.
  • Couple will give informed consent and will consent to have their medical history examined by the research group.

Exclusion Criteria:

  • Couple has not finished building their family.
  • Couple has embryos but they have not been stored for > or = to 5 years.
  • Couple will not submit to an interview, blood tests, or physical exam by a physician.
  • Couple refuse to give informed consent, or will not consent to have their medical history examined by the research group.
  • Couple has spent an extended period of time in exclusion countries (HIV or vCJD risk).
  • Couple tests positive for exclusion viruses (as listed in the Informed Consent).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00353197


Contacts
Contact: Benjamin E. Reubinoff, M.D. PhD. 011-972-2-677-7111 ext 74569 reubinof@md.huji.ac.il
Contact: Nitzchiya Geva, B.S.N. 011-972-2-677-7111 ext 7174 NitshiaG@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Recruiting
Jerusalem, Israel, 91120
Contact: Arik Tzukert, DMD    011-972-2-677-7111 ext 76095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    011-972-2-677-7111 ext 77572    lhadas@hadassah.org.il   
Principal Investigator: Benjamin E. Reubinoff, M.D. PhD.         
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Benjamin E. Reubinoff, M.D. PhD. Hadassah Medical Organization
  More Information

Additional Information:
Publications:
Responsible Party: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00353197     History of Changes
Other Study ID Numbers: 33-26.07.02-HMO-CTIL
First Submitted: July 16, 2006
First Posted: July 18, 2006
Last Update Posted: March 1, 2017
Last Verified: February 2017

Keywords provided by Hadassah Medical Organization:
IVF
embryos
research
donation
surplus
stem cells

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female